Patient Information | Important Safety Information | For Healthcare Professionals
More choices surround me

Targeted therapy


Targeted therapies represent one of the most exciting and promising areas of cancer research. They are designed to act on, or “target,” specific sites on or in cancer cells to stop or slow tumor growth.

Normally, cells undergo a steady process of growth, dividing when necessary to produce new cells. As cells age, they die and new cells take their place. Cancer cells don’t follow this normal process. New cells form, grow out of control, and live longer than normal cells.

Targeted therapies are designed to stop or slow cancer growth by interfering with steps in the abnormal cell growth process. They do this by blocking the signals that tell the cells when to grow or produce more cells.2

The HER2 protein plays an important role in how cancer cells grow, multiply, and survive.18 Due to its specific action on the HER2 receptors, TYKERB is classified as a HER2-targeted treatment.

Ask the Expert

Ask the Experts
Get answers to your questions about TYKERB.

Get More InformationGet More Information Get updates from www.TYKERB.com.

Tykerb Cares

Get support from Tykerb® CARES

Indication
TYKERB is indicated in combination with Xeloda® (capecitabine) for the treatment of patients with advanced or metastatic breast cancer whose tumors overexpress HER2 and who have received prior therapy including an anthracycline, a taxane, and Herceptin® (trastuzumab).

Important Safety Information
Some women may develop liver damage while taking TYKERB. The cause of this damage is not known. In some cases, liver damage may be severe and may cause death. Your doctor should test your liver before and during treatment with TYKERB to check for signs of liver damage. You should contact your doctor if you have itching, yellow eyes or skin, dark urine, pain in your right upper side of your belly or feel very tired. If you develop liver damage during your treatment, your doctor may tell you to stop taking TYKERB. Before taking TYKERB, tell your doctor if you have liver problems. You may need a lower dose of TYKERB.

Before taking TYKERB, tell your doctor if you have heart problems. As with other treatments for HER2-positive advanced or metastatic breast cancer, there have been reports of changes in how the heart pumps blood through the body and how the heart beats. Call your doctor right away if you are short of breath, have rapid heartbeats (palpitations), or feel very tired.

Some people taking TYKERB have reported diarrhea. In some cases, diarrhea can be severe. Call your doctor right away if you have diarrhea. It is important to manage diarrhea with medicine as soon as it begins. Severe diarrhea may need to be treated with electrolytes and fluids given by mouth or by vein. Treatment with TYKERB may have to be delayed for a while or stopped completely.

If you have a dry cough or have shortness of breath, talk with your doctor. These may be signs of inflammation in the lungs.

Women should not become pregnant when taking TYKERB because the unborn baby may be harmed.

The most common side effects reported by patients taking TYKERB and Xeloda were diarrhea; vomiting; feeling sick to your stomach (nausea); feeling tired; red, painful hands and feet; and rash.

Tell your doctor about all the medicines you take, including prescription and nonprescription medicines and herbal and dietary supplements.

Because TYKERB is currently indicated to be taken with another medicine called Xeloda, be sure to talk with your doctor about any medicines and supplements that should be avoided when taking Xeloda.

Please see complete US Prescribing Information for TYKERB.

Xeloda is a registered trademark of Roche Laboratories Inc.

Herceptin is a registered trademark of Genentech, Inc.

Photos are for illustrative purposes only.

     

     

This website is funded and developed by GlaxoSmithKline.
This site is intended for US residents only.
© 1997-2010 GlaxoSmithKline. All Rights Reserved.
Legal Notices | Privacy Statement | Contact Us